Japanese subgroup analysis of GLIMMER: A global Phase 2b study of linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

Atsushi TanakaMasanori AtsukawaKeiji TsujiKazuo NotsumataAkari SuyamaHiroshi ItoSugato DasRobyn von MaltzahnMegan M McLaughlin

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2023)

Therapeutic responses and safety of linerixibat were consistent between the Japanese and overall populations of GLIMMER. Linerixibat may provide an effective treatment option for cholestatic pruritus in patients with PBC. This article is protected by copyright. All rights reserved.

Keyphrases

liver injury
randomized controlled trial
combination therapy
atopic dermatitis
genetic diversity